{"entity":{"id":"fiona-blackhall","kind":"person","name":"Fiona Blackhall","aka":[],"tldr":"Fiona Blackhall is a thoracic oncologist leading small-cell lung cancer trials and biomarker research at The Christie.","summary":"Fiona Blackhall is Professor of Thoracic Oncology at the University of Manchester and a consultant at The Christie NHS Foundation Trust. Her specialisms are lung cancer, small-cell lung cancer and biomarker-driven trials. She leads thoracic oncology research in Manchester with trials in small-cell and non-small-cell lung cancer and studies of blood-based biomarkers. Her papers include an analysis of the prognostic value of circulating tumour cells in limited-stage small-cell lung cancer within the CONVERT radiotherapy trial, the randomised ERCC1 biomarker trial comparing platinum and non-platinum therapy in advanced non-small-cell lung cancer, and a review of liquid biopsy as a route to improved care in small-cell lung cancer. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blackhall%20F%5BAuthor%5D%20small%20cell%20lung"}],"tags":[],"related":[],"cancers":["sclc","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Thoracic Oncology, University of Manchester; Consultant, The Christie","institutionId":"the-christie","specialisms":["Lung cancer","Small-cell lung cancer","Biomarker-driven trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Blackhall%20F%5BAuthor%5D%20small%20cell%20lung"}],"papers":[{"title":"Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz122"},{"title":"Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non–Small-Cell Lung Cancer: ERCC1 Trial (ET)","journal":"Journal of Clinical Oncology","year":2017,"doi":"10.1200/jco.2016.68.1841"},{"title":"Liquid Biopsy in Small Cell Lung Cancer—A Route to Improved Clinical Care?","journal":"Cells","year":2020,"doi":"10.3390/cells9122586"},{"title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2307980","doi":"10.1056/NEJMoa2307980"}],"orcid":"0000-0001-8716-3395"},"route":"/people/fiona-blackhall/","neighbours":{"cancer":[{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"institution":[{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","route":"/institutions/cruk-manchester-institute/"},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/"},{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/"}],"idea":[{"id":"idea-bio2-ctc-culture-functional-testing","kind":"idea","name":"Grow blood-borne tumour cells to test drugs on the cells that actually spread","route":"/ideas/idea-bio2-ctc-culture-functional-testing/"}],"paper":[{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/"}]}}